Evidence map›Paper›PMID 27987203›Full record

ReviewOncology (Williston Park, N.Y.)2016

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.

Karen M Winkfield, Ranjana H Advani, Leslie K Ballas, Bouthaina S Dabaja, Sughosh Dhakal, Christopher R Flowers, Chul Soo Ha, Bradford S Hoppe, David B Mansur, Nancy P Mendenhall and 8 more

Open access · greenAbstract readReview
In one paragraph

Review in Oncology (Williston Park, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 15 institutions in 1 country.

Karen M Winkfield
Ranjana H Advani
Leslie K Ballas
Bouthaina S Dabaja
Sughosh Dhakal
Christopher R Flowers
Chul Soo Ha
Bradford S Hoppe
David B Mansur
Nancy P Mendenhall
Monika L Metzger
John P Plastaras
Kenneth B Roberts
Ronald Shapiro
Sonali M Smith
Stephanie A Terezakis
Anas Younes
Louis S Constine
University of Florida · USUniversity of Rochester · USCase Western Reserve University · USEmory University · USIndiana University · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USSouthern California University for Professional Studies · USStanford University · USSt. Jude Children's Research Hospital · USThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · USUniversity of Chicago · USWake Forest University · USYale University · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

This topic addresses the management of recurrent Hodgkin lymphoma. While autologous stem cell transplantation may be appropriate for select cases of recurrent disease following comprehensive combined-modality therapy, other options exist for patients treated with lower-dose therapy for early-stage disease. Additionally, innovative targeted therapies provide newer salvage options to consider. The American College of Radiology Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation, or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.

Indexed as

Combined Modality TherapyHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansPractice Guidelines as TopicRecurrenceTransplantation, Autologous

Identifiers

PMID27987203
PMCPMC7440297
OpenAlexW2576518113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.